Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378626 | 0.85 | DGAT1 (0.46) | LMNAMAPTDGAT1UCHL1CYP1A2 | |
| SCHEMBL23534276 | 0.82 | SNCA (0.39) | DGAT1CYP1A2CYP2D6TSHRALDH1A1 | |
| SCHEMBL29778784 | 0.82 | DGAT1 (0.39) | LMNAMAPTDGAT1UCHL1CYP1A2 | |
| SCHEMBL2377085 | 0.82 | UCHL1 (0.42) | LMNAMAPTDGAT1UCHL1CYP1A2 | |
| SCHEMBL2377518 | 0.82 | UCHL1 (0.44) | LMNAMAPTDGAT1UCHL1CYP1A2 | |
| SCHEMBL23641247 | 0.82 | DGAT1 (0.39) | LMNAMAPTDGAT1UCHL1CYP1A2 | |
| SCHEMBL24696660 | 0.81 | DGAT1 (0.38) | LMNAMAPTDGAT1UCHL1CYP1A2 | |
| SCHEMBL30039774 | 0.81 | DGAT1 (0.38) | LMNAMAPTDGAT1UCHL1CYP1A2 | |
| SCHEMBL20657655 | 0.79 | DGAT1 (0.52) | DGAT1UCHL1SNCALPLLIPG | |
| SCHEMBL2377024 | 0.79 | SNCA (0.39) | LMNAMAPTDGAT1UCHL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-12-23 | — | — | US | disclosed |
| EP-2239261-A1 | PYRROLOPYRIMIDIN DERIVATIVE FOR USE AS PI3K INHIBITOR, AND USE THEREOF | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | LMNA 4407/4885MAPT 4385/4885DGAT1 2729/4885 |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CSNK1A1, CSK, CSNK1A1L | LMNA 2167/4885MAPT 4731/4885DGAT1 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.